Clearmind Medicine Inc. (CMND) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Clearmind Medicine Inc. (CMND) dropped -3.46% to $5.85, trading at 2% of its 52-week range ($5.25 – $2688). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity Therapeutics
For questions about this article or underlying research, email help@trefis.com.
Milestone advances Clearmind’s clinical program as the company continues to develop CMND‑100 as a potential novel therapeutic candidate for alcohol use disorder Vancouver, Canada, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Clearm
Clearmind Medicine Inc. (Nasdaq: CMND) ("Clearmind" or the "Company"), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogens for scalable treatment
For questions about this article or underlying research, email help@trefis.com.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CMND today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CMND. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Clearmind Medicine Inc. (CMND) ranks #400 by composite RQD confidence (48/100, grade D) and #980 by equity capitalization ($3.0M). Within this direct 5-issuer industry benchmark cohort, CMND leads on earnings valuation at N/A trailing P/E, while MBIO leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SXTP currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with CMND at 48/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CMND
ACTIVE
Clearmind Medicine Inc. | D | 48/100 | — | — | — | -3.46% | $3.0M | Benchmark Subject |
| MBIO Mustang Bio Inc. | D- | 43/100 | — | — | -35.0% | +9.00% | $3.0M | /mbio-vs-cmnd → |
| DCOY Decoy Therapeutics Inc. | D | 45/100 | — | — | -35.0% | +11.82% | $2.9M | /dcoy-vs-cmnd → |
| JUNS Jupiter Neurosciences Inc. | E | 33/100 | — | 80.6% | -35.0% | -5.20% | $3.1M | /juns-vs-cmnd → |
| SXTP 60 Degrees Pharmaceuticals Inc. | D | 50/100 | — | 22.3% | -35.0% | +11.87% | $3.3M | /sxtp-vs-cmnd → |
Clearmind Medicine Inc. (CMND) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $3.0M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-01, Clearmind Medicine Inc. (NASDAQ: CMND) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $5.85 (-3.46% 1D, market cap $3.0M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CMND ranks #400 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CMND carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MBIO (Mustang Bio Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $3.0M) and DCOY (Decoy Therapeutics Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.9M). Among the 5-stock peer group, CMND leads on earnings multiple (N/A) while MBIO leads on capital efficiency (-35.0% ROIC).
For Clearmind Medicine Inc. (CMND), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #400 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.
CMND last traded at $5.85 (-3.46% on volume of 4,383 shares), positioning the stock -27.60% below its 50-day simple moving average ($8.08) and -87.79% below its 200-day simple moving average ($47.91). Across its 52-week range of $5.25 to $2,688.00, CMND sits at the 0.0% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.12 to $6.58).
Why CMND Stock dropped -3.46% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.